Cargando…
Current advances and outlooks in immunotherapy for pancreatic ductal adenocarcinoma
Pancreatic ductal adenocarcinoma (PDAC) is an incurable cancer resistant to traditional treatments, although a limited number of early-stage patients can undergo radical resection. Immunotherapies for the treatment of haematological malignancies as well as solid tumours have been substantially impro...
Autores principales: | Fan, Jia-qiao, Wang, Meng-Fei, Chen, Hai-Long, Shang, Dong, Das, Jugal K., Song, Jianxun |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
BioMed Central
2020
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7023714/ https://www.ncbi.nlm.nih.gov/pubmed/32061257 http://dx.doi.org/10.1186/s12943-020-01151-3 |
Ejemplares similares
-
Pancreatic ductal adenocarcinoma immune microenvironment and immunotherapy prospects
por: Li, Ke-Yu, et al.
Publicado: (2020) -
Macrophage-based immunotherapy for the treatment of pancreatic ductal adenocarcinoma
por: Beatty, Gregory L
Publicado: (2013) -
Exploiting the neoantigen landscape for immunotherapy of pancreatic ductal adenocarcinoma
por: Bailey, Peter, et al.
Publicado: (2016) -
Mechanisms Governing Immunotherapy Resistance in Pancreatic Ductal Adenocarcinoma
por: Schmiechen, Zoe C., et al.
Publicado: (2021) -
Tumor microenvironment in pancreatic ductal adenocarcinoma: Implications in immunotherapy
por: Smith, Caitlyn, et al.
Publicado: (2022)